Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity

Area of Science:

• Cardio-oncology
• Cancer Therapeutics
• Cardiovascular Safety

Background:

• Cardiovascular toxicity is a major limitation of current antineoplastic agents.
• This toxicity can lead to serious adverse events, impacting patient treatment and outcomes.
• The need for effective cancer treatments with reduced cardiac side effects is critical.

Purpose of the Study:

• To explore the potential of cardio-oncology in identifying novel anti-cancer therapeutics.
• To highlight agents that inhibit cancer cell proliferation without inducing cardiotoxicity.
• To discuss the clinical introduction of cardio-safe compounds for improved cancer patient care.

Main Methods:

• Review of emerging research in cardio-oncology.
• Identification and analysis of novel cardio-safe anti-cancer compounds.
• Evaluation of mechanisms of action for inhibiting cancer growth and preserving cardiac function.

Main Results:

• The field of cardio-oncology is identifying potent anti-cancer agents.
• Specific compounds, such as ERK dimerization inhibitors and BAX allosteric inhibitors, show promise.
• These agents are being developed to selectively target cancer cells while minimizing cardiotoxicity.

Conclusions:

• Future clinical practice may incorporate cardio-safe compounds.
• Oncologists can potentially avoid cardiological complications associated with cancer therapies.
• Advancements in cardio-oncology offer a path to safer and more effective cancer treatment.